Rebus Holdings Inc (RBSH)

[Mrragu]

From 10-K ...Possible clinical trials to begin later in 2022 or early 2023???

Between September 2021 and February 2022, our CMO manufactured to GMP standards; both our adenosine A2A receptor antagonist as well as the nano- or microparticle formulation for intratumoral delivery known as RT-AR001. We have sufficient material to take us through the IND and initial clinical studies.
We have completed in-vitro testing of our adenosine A2A receptor antagonist and will begin in-vivo animal testing with RT-AR001 in Q2 2022. The Company plans to provide a further update on RT-AR001’s clinical development in the second half of 2022.